This search combines search strings from the content search (i.e. "Full Text", "Author", "Title", "Abstract", or "Keywords") with "Article Type" and "Publication Date Range" using the AND operator.
Beilstein J. Nanotechnol. 2019, 10, 2217–2228, doi:10.3762/bjnano.10.214
Scheme 1: Schematic representation of CuFe2O4/HYPS/cisplatin nanoformulation.
Figure 1: Powder XRD patterns of CuFe2O4/HYPS with different Cu concentrations (x = 0.08, 0.10, 0.12, 0.15 an...
Figure 2: BET adsorption–desorption isotherm and pore size distribution of (a) HYPS and (b) 30 wt% CuFe2O4/HY...
Figure 3: FTIR spectra of HYPS and 30 wt % CuFe2O4/HYPS.
Figure 4: Transmission electron microscopy of (a, b) 30 wt % CuFe2O4/HYPS at different scale magnifications a...
Figure 5: Vibrating sample magnetometer spectrum of 30 wt % CuFe2O4/HYPS.
Figure 6: DR-UV–visible spectra of (a) CuFe2O4/HYPS and (b) cisplatin/CuFe2O4/HYPS.
Figure 7: Percentage cumulative cisplatin release in tumor pH 5 conditions for 72 h in (a) CuFe2O4/HYPS, (b) ...
Figure 8: Percentage cell viability using MTT assay on the MCF-7 cell line. The cells were treated with the f...
Figure 9: EC50 values for each condition. Data sets from Figure 8 were used to extrapolate the line equation of each ...